Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 2 clinical trials
Post Marketing Surveillance on Safety Evaluation of POMALYST® (Pomalidomide) Treatment of Multiple Myeloma in Korea (Pomalyst PMS)

PMS period: 09Jun2017 ~ 08Jun2023 Target no.: 600patients indication: POMALYST in combination with dexamethasone is indicated in the treatment of patients with relapsed and refractory

dexamethasone
pomalidomide
refractory multiple myeloma
lenalidomide
pomalyst
  • 19 views
  • 24 May, 2022
  • 29 locations
Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway in Multiple Myeloma

with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond

cancer
hematologic malignancy
revlimid
pomalidomide
lenalidomide
  • 0 views
  • 26 Nov, 2021
  • 1 location